Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib followed by Ipilimumab in BRAF-mutated Advanced Melanoma
NCT01673854Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2012
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Participants Who Received Ipilimumab and Who Had Grade 3-4 Drug-related Skin Adverse Events up to 3 years. Started Sep 2012; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01673854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01673854.